By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On February 13, 2024, the U.S. Food and Drug Administration granted approval for the use of
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On December 13, 2023, the U.S. Food and Drug Administration granted approval to eflornithine (IWILFIN, USWM,
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY The U.S. Food and Drug Administration gave its approval for the use of enfortumab vedotin-ejfv (Padcev,
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On December 14, 2023, the U.S. Food and Drug Administration granted approval to belzutifan (Welireg, Merck
By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center Tucatinib, a HER2-directed tyrosine kinase inhibitor (TKI), has been approved in
By Dr. Arya Mariam Roy of Roswell Park Comprehensive Cancer Center Development of endocrine resistance remains a challenge in the management of
By Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center Data from two phase III trials showed that adding immune checkpoint inhibition
December 6th 2023 / 12:15 PM PST By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 15, 2023, the U.S. Food and Drug
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On November 16, 2023, the U.S. Food and Drug Administration approved Pembrolizumab (Keytruda) plus fluoropyrimidine- and
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On the date of approval, the U.S. Food and Drug Administration approved Nirogacestat (Ogsiveo) for adult